A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.

被引：0
|
作者：
Raj, SKS
Basche, M
Gore, L
Grolnic, S
Hunt, J
O'Bryant, CL
Morrow, M
Creese, B
Kangas, M
Sawlwin, D
Eckhardt, SG
Holden, SN
Holden, SN
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Progen Ind Ltd, Darra, Australia
[3] Omnicare Clin Res, Sydney, NSW, Australia
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6152S / 6152S
页数：1
相关论文
共 50 条
  • [31] Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Monica Mita
    Alain Mita
    John Sarantopoulos
    Chris H. Takimoto
    Eric K. Rowinsky
    Ofelia Romero
    Patrizia Angiuli
    Cecilia Allievi
    Amy Eisenfeld
    Claire F. Verschraegen
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 287 - 295
  • [32] Phase I study of TLK286 administered weekly in advanced refractory malignancies.
    Rosen, LS
    Kadib, L
    Laxa, B
    Reiswig, L
    Brown, J
    Brown, GL
    Lum, R
    Schow, S
    Maack, C
    Vollmer, C
    Nichols, A
    Henner, WD
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3713S - 3713S
  • [33] Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
    Spiridonidis, CH
    Laufman, LR
    Jones, J
    Rhodes, VA
    Wallace, K
    Nicol, S
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3866 - 3873
  • [34] Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.
    Papandreou, CN
    Pagliaro, L
    Millikan, R
    Daliani, D
    Herrmann, J
    Hong, Y
    Smith, M
    Adams, J
    Elliot, P
    Lightcap, E
    McCormack, T
    Pien, C
    Newman, R
    Logothetis, CJ
    CLINICAL CANCER RESEARCH, 1999, 5 : 3730S - 3730S
  • [35] PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials.
    Gautam, AM
    Ferro, V
    Wilson, EA
    Freeman, C
    Parish, C
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9037S - 9037S
  • [36] A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies.
    Friedman, DT
    Goel, S
    Desai, K
    Verdier-Pinard, D
    Kaubisch, A
    Bulgaru, A
    Camacho, F
    Goldberg, G
    Mani, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 155S - 155S
  • [37] Phase I study of BMS-188797, a new taxane analog, given weekly in patients with advanced malignancies.
    Goldstein, L
    Vaders, L
    Rogatko, A
    Bulanhagui, C
    Gupta, E
    Tarby, C
    Sonnichsen, D
    Gustafson, N
    Gallant, G
    CLINICAL CANCER RESEARCH, 2000, 6 : 4579S - 4579S
  • [38] A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies.
    Giles, FJ
    Fischer, T
    Cortes, J
    Beck, J
    Ravandi-Kashani, F
    Garcia-Manero, G
    Kantarjian, HM
    Peng, B
    Rae, PE
    Laird, G
    Sharma, S
    Dugan, M
    Albitar, M
    Bhalla, KM
    BLOOD, 2004, 104 (11) : 499A - 499A
  • [39] A phase I clinical and pharmacokinetic study of ipifarnib in combination with docetaxel in patients with advanced solid malignancies
    Awada, Ahmad
    Zhang, Steven
    Gil, Thierry
    de Valeriola, Dominique
    Lalami, Yassine
    De Porre, Peter
    Piccart-Gebhart, Martine J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (05) : 991 - 1003
  • [40] A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.
    Cohen, E. E.
    Sharma, M.
    Janisch, L. A.
    Stadler, W. M.
    Kang, S. P.
    Fleming, G. F.
    Ratain, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345